Survodutide
Also known as: BI 456906, GLP-1/Glucagon Dual Agonist
Overview
Survodutide (BI 456906) is an investigational dual agonist of GLP-1 (glucagon-like peptide-1) and glucagon receptors, developed by Boehringer Ingelheim. Unlike GLP-1/GIP dual agonists (tirzepatide), survodutide combines GLP-1-driven satiety and insulin secretion with glucagon-driven hepatic fat oxidation and energy expenditure. This mechanism is particularly relevant to non-alcoholic steatohepatitis (NASH) and metabolic-associated steatotic liver disease (MASLD), where glucagon receptor activation reduces hepatic lipid accumulation.
Mechanism of Action
Survodutide co-activates GLP-1 receptors (reducing appetite, slowing gastric emptying, stimulating insulin secretion) and glucagon receptors (increasing hepatic fat oxidation, thermogenesis, and energy expenditure). The glucagon component uniquely reduces hepatic steatosis by promoting fatty acid β-oxidation and decreasing de novo lipogenesis. GLP-1 activity counteracts glucagon's hyperglycemic potential, maintaining glycemic balance while allowing glucagon-driven metabolic benefits.
Potential Benefits
- Significant body weight reduction (Phase II: up to 18.7% at 48 weeks)
- Reduction in hepatic fat content (NASH/MASLD indication)
- Improved lipid profiles with glucagon-driven hepatic fat oxidation
- Dual mechanism addresses both appetite and energy expenditure
- Potential superiority to pure GLP-1 agonists for liver fat reduction
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Typical Range | 0.6-4.8 mg/week (Phase II range) |
| Beginner | 0.6 mg/week titration start |
| Intermediate | 1.2-2.4 mg/week |
| Advanced | 3.6-4.8 mg/week (Phase II maximum doses) |
| Cycle Duration | Ongoing therapeutic use; titration-based |
| Cycle Off | Not designed for cycling |
Dosing based on Phase II clinical trial protocols; final approved dosing not yet established. Expect slow titration to manage GI side effects.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Subcutaneous Injection High
Once-weekly SC injection; Phase 2 doses: 0.6–4.8 mg/week. Phase 3 dose selection based on Phase 2 data. Standard GLP-1 injection technique.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving Survodutide:
Metabolic Health Stack
Combines Survodutide with MOTS-c (mitochondrial metabolism) and AOD-9604 (lipolysis) for metabolic optimization.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Typical Vial Size | Pre-filled pen device (clinical trial); research vials 1-5mg |
|---|---|
| BAC Water | N/A for clinical formulation; research vials use 1-2ml BAC water |
| Storage | Refrigerate at 2-8°C |
| Shelf Life | 24 months unopened per manufacturer |
Need exact syringe measurements?
Amino Acid Sequence
Proprietary sequence; dual GLP-1/glucagon receptor agonist peptide
Side Effects & Safety
- Nausea (most common, dose-dependent)
- Vomiting and diarrhea
- Decreased appetite
- Potential for hepatotoxicity monitoring required (glucagon component)
- Hypoglycemia risk lower than pure glucagon agonists due to GLP-1 counterbalance
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
Drug Interactions
- Oral Medications (general):
Pharmacokinetics
| Half-Life | ~7 days (fatty acid modification; once-weekly dosing) |
|---|---|
| Storage | Refrigerate at 2–8°C; do not freeze; protect from light |
Synergistic Compounds
The following compounds have been studied alongside Survodutide for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA Staff Reviewers Say ‘No’ to 7 Compounded Peptides Ahead of July PCAC Vote
FDA staff reviewers urged against adding seven popular peptides to the 503A bulks list ahead of the July PCAC meeting, citing weak human data and safety uncertainty.
FDA reviewers urge ‘no’ on BPC-157, TB-500, MOTS-c ahead of July 2026 compounding vote
FDA reviewers’ June 29 briefings recommend against listing seven popular peptides for 503A compounding, citing limited human data and immunogenicity risk.
Medicare Starts Paying for Obesity Drugs Today — Bridge Program Opens $50 Access for Millions
Medicare's new $50 Bridge program covering Wegovy, Zepbound, Foundayo, and oral Wegovy for obesity launched July 1 — the first Medicare weight-loss benefit.
FDA staff urges caution on compounded peptides ahead of July advisory meeting
Ahead of the July 23–24 Pharmacy Compounding Advisory Committee meeting, FDA staff briefings recommend against listing seven popular peptides for compounding.